Logo Università degli Studi di Milano



 
 
News  

MOGLYNET

moglynet, phd programma, marie curie action, itn


MOGLYNET

PhD programme in DRUG DISCOVERY AND DEVELOPMENT 2015-2019

Scholarship Programme Promoting Institutional Cooperation and Mobility for 12 early stage researchers

Mission

The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry, supported by other institutions/organizations, join their forces for:

  • Creating a common platform of knowledge and language for 12 early stage researchers(ESR) working in the Drug Discovery and Development area aiming to convey complementary Pharma-skills
  • Exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry and regulatory authorities
  • Establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on

Doctorate Courses/Schools

  • University of Milan: Pharmaceutical Sciences
  • University of Milan: Experimental and Clinical Pharmacological Sciences
  • University of Aberdeen: Graduate School in Life Sciences and Medicine
  • University of Antwerp: Antwerp Doctoral School
  • University of Barcelona Doctoral School
  • University of Leiden: Graduate School of Leiden University Medical Center

Research project

Atherosclerotic cardiovascular disease is the major cause of death in the western world. Thanks to cholesterol-lowering drugs, the lifespan and wellbeing of patients have been significantly improved. However, a large group of patients does not fully benefit from current lipid-lowering strategies.
Our multidisciplinary approach is focused on counteracting neovessel formation to prevent plaque rupture and its cardiovascular complications, thus leading to a more effective therapy for atherosclerosis.

Research methodology and approach

The MoGlyNet consortium is strongly multidisciplinary and takes advantage of a number of different state-of-the-art technologies and methodologies:

  • Computational chemistry and synthesis
  • Bioanalytics and biophysics
  • In vitro and in vivobiological evaluation
  • Imaging
  • Metabolomic and Proteomic studies
  • Oxidative stress studies

Beneficiaries

  • University of Milan (Pharmaceutical Sciences and Pharmacological and Biomolecular Sciences Departments), Italy – Coordinating University
  • University of Aberdeen (Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition), UK
  • University of Antwerp (Laboratory of Physiopharmacology), Belgium
  • University of Barcelona (Department of Biochemistry and Molecular Biology), Spain
  • Leiden University Medical Center (Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine), The Netherlands

Partners and Associations

  • Bayer HealthCare Manufacturing S.r.l., Italy
  • Biomax Informatics AG, Germany
  • HistoGeneX N.V., Belgium
  • KemoTech Srl, Italy
  • Linkcare Health Services, Spain
  • Ingenus Pharmaceutical GmbH, Switzerland
  • PPD Italy srl, Italy
  • EIPG (European Industrial Pharmacists Group)
  • EAS (European Atherosclerosis Society)
  • EDQM (European Directorate for the Quality of Medicines


CONTACTS
secretary@moglynet.com
Tel. +390250314471
Fax +390250314476

Flyer

Website

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 67552

01 September 2015
Back to top